Kayne Anderson Rudnick Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-7	Closed	-$1K	–	747
2020 Q4	$1K	Buy	+7	New	+$900	﹤0.01%	684
2020 Q3	–	Sell	-4	Closed	–	–	588
2020 Q2	$0	Hold	4	–	–	﹤0.01%	653
2020 Q1	$0	Sell	4 -10	-71%	-$981	﹤0.01%	695
2019 Q4	$2K	Buy	14 +10	+250%	+$1.07K	﹤0.01%	599
2019 Q3	$0	Hold	4	–	–	﹤0.01%	576
2019 Q2	$1K	Buy	+4	New	+$516	﹤0.01%	539

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's ALXN Position: Q1 2021 in Review

Kayne Anderson Rudnick Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 7 shares — an estimated $1K sold.

Kayne Anderson Rudnick Investment Management first reported a position in ALXN in Q2 2019 and held it in 6 quarters. The position peaked at $2K in Q4 2019. 753 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

Kayne Anderson Rudnick Investment Management reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Kayne Anderson Rudnick Investment Management sold 7 Alexion Pharmaceuticals shares in Q1 2021, an estimated $1K.
Kayne Anderson Rudnick Investment Management first reported a position in Alexion Pharmaceuticals in Q2 2019 and held it in 6 quarters.
Kayne Anderson Rudnick Investment Management's Alexion Pharmaceuticals position peaked at $2K in Q4 2019.
753 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q1 2021, filed 17 May 2021.